Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Dec;140(6):1716-1718.
doi: 10.1016/j.jaci.2017.05.033. Epub 2017 Jun 15.

A randomized, placebo-controlled, double-blinded, crossover trial of pioglitazone for severe asthma

Maryann Kaler  1 , Amisha V Barochia  1 , Nargues A Weir  2 , Rosemarie A Cuento  1 , Mario Stylianou  3 , Mark J Roth  4 , Armando C Filie  4 , Ellen C Vaughey  5 , Steven D Nathan  6 , Stewart J Levine  7
Affiliations
Randomized Controlled Trial

A randomized, placebo-controlled, double-blinded, crossover trial of pioglitazone for severe asthma

Maryann Kaler et al. J Allergy Clin Immunol. 2017 Dec.

Abstract

The PPAR-γ agonist, pioglitazone, was associated with significant side effects and did not improve the primary outcome measure of the Juniper Asthma Quality of Life Questionnaire (AQLQ) score in severe asthmatics. We conclude that no further studies should be performed with pioglitazone for severe asthma.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Flow of subjects through the study showing number of participants screened, randomized, withdrawn, and completed
Participants who were excluded did not meet the pre-specified inclusion criteria.
Figure 2
Figure 2. Comparison of pioglitazone and placebo treatment periods for the primary end-point of asthma quality of life questionnaire score and secondary end-points of asthma symptoms and control
Panel A. Juniper asthma quality of life (AQLQ) score. Panel B. Juniper asthma control questionnaire (ACQ) score. Panel C. Daily asthma symptom score. Panel D. Number of puffs of rescue β2-agonist inhaler per day. Panel E. Asthma symptom-free days (%). Panel F. Nights with asthma symptoms (%). Panel G. Number of mild asthma exacerbations. Panel H. Number of severe asthma exacerbations. Data for daily asthma symptom score, rescue β2-agonist inhaler use, asthma symptom-free days, nights with asthma symptoms are averages for each period based upon the days that subjects reported data. P values are shown for differences between the pioglitazone and placebo treatment periods.
See this image and copyright information in PMC

References

    1. Straus DS, Glass CK. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol. 2007;28:551–8. - PubMed
    1. Belvisi MG, Hele DJ, Birrell MA. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation. Eur J Pharmacol. 2006;533:101–9. - PubMed
    1. Ward JE, Tan X. Peroxisome proliferator activated receptor ligands as regulators of airway inflammation and remodelling in chronic lung disease. PPAR Res. 2007;2007:14983. - PMC - PubMed
    1. Rinne ST, Feemster LC, Collins BF, Au DH, Perkins M, Bryson CL, et al. Thiazolidinediones and the risk of asthma exacerbation among patients with diabetes: a cohort study. Allergy Asthma Clin Immunol. 2014;10:34. - PMC - PubMed
    1. Sandhu MS, Dimov V, Sandhu AK, Walters RW, Wichman T, Casale T. The use of the peroxisome proliferator-activated receptors gamma agonist rosiglitazone to treat airway hyperreactivity. Ann Allergy Asthma Immunol. 2012;109:75–7. - PubMed

Publication types